TLX
Trans-Lux Corp.
NASDAQ · Healthcare · Biotechnology · AU
$9.57
+5.92%Year over year
Reported trailing growth
- Revenue
- -6.7%
- EBITDA
- -66.0%
- EBIT
- —
- EPS
- -15.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -82.5%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +70.2%
- EBITDA
- +50.9%
- EBIT
- +5.0%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026